The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Tema Oncology ETF CANC
Morningstar’s Analysis CANC
Will CANC outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 38.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Regeneron Pharmaceuticals Inc | 5.56 | 1.0 Mil | Healthcare |
Merck & Co Inc | 5.33 | 992,453 | Healthcare |
Daiichi Sankyo Co Ltd | 4.18 | 777,204 | Healthcare |
AstraZeneca PLC | 3.88 | 721,571 | Healthcare |
Novartis AG Registered Shares | 3.55 | 660,382 | Healthcare |
Amgen Inc | 3.24 | 602,402 | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.21 | 598,130 | Healthcare |
Illumina Inc | 3.08 | 573,577 | Healthcare |
Blueprint Medicines Corp | 3.00 | 557,296 | Healthcare |
argenx SE ADR | 2.98 | 555,144 | Healthcare |